VANCOUVER, B.C., February 3, 2022 /PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary mental health care technology and research of psychedelics, today announced the hiring of Dr. Clare PurvisFormer Vice President of Clinical Product and Content Development at Headspace Inc., to the new role of Chief Product Officer for the company to focus on building and expanding the reach of iSTRYM, its digital therapy platform.
“As care becomes more personalized, the need has never been greater for high-quality, scalable digital therapies in the mental health space, and I’m excited to join the MINDCURE team at the forefront of the progress being made.” Dr. Purvis said, adding, “iSTRYM has proven itself in a rapidly growing market and I believe it has the potential to become a dominant force as the product of choice for clinics using technology-assisted therapies.”
While at Headspace, Dr. Purvis was part of the executive leadership team responsible for clinical and scientific strategy, helped establish the company’s overall strategy, and oversaw new product development in behavioral and mental health beginning in 2019. He currently serves as a member of the Brightline Member Clinical Advisory Board, which provides a technology-based approach to pediatric behavioral health.
“It is a pivotal and proud moment in MINDCURE’s journey as we welcome Dr. Purvis to the team. Clare’s experience, insights and reputation as a thought leader and science-backed leader in the space of fast-growing digital mental health will be an invaluable asset.” in addition to MINDCURE’s growth in the mental health industry,” said MINDCURE President and CEO Kelsey Ramsden. “As MINDCURE moves forward to make Mental WealthTM a reality for more people, Clare will lead the delivery of a truly transformative, high-value experience for therapists, patients and ultimately payers alike,” added Ramsden.
MINDCURE’s product solution, iSTRYM, is expanding to cover a broader market that will include clinics operating in both psychedelic-assisted psychotherapy and general psychotherapy and psychiatry. It is for this purpose that MINDCURE is introducing the role of Product Manager to deliver the above initiatives. After successfully building your initial product as CTO, geoff belair will lead the migration of our technology team to an engineering division, with a focus on data strategy and building the MINDCURE AI models that support the product. In his new role as Vice President of Engineering, Mr. Belair will report to the CPO and work closely with Dr. Purvis to ensure success as MINDCURE moves toward commercialization.
“I would like to thank Mr. Belair for his visionary platform architecture and look forward to his continued service in this new role,” said MINDCURE President and CEO. Kelsey Ramsden.
Dr. Purvis is a licensed clinical psychologist and received her Doctorate in Psychology from the PGSP-Stanford Consortium, where she trained in the Stanford Department of Psychiatry and Behavioral Sciences. She serves as an Affiliate Fellow at Stanford University Clinical Excellence Research Center, where he provides consultation on the use of technology to make excellent health care more affordable.
MINDCURE also announces that Daniel Herrera, currently Vice President of Growth and Strategic Partnerships, has been promoted to the role of Chief Growth Officer as a result of his exceptional performance to date. His continued work in this role will propel MINDCURE forward as we move closer to commercializing iSTRYM and plan for significant growth in the years to come.
ISTRYM is currently associated with 20 clinics in North America during its closed beta launch. Full commercialization of the platform is expected in the second quarter of 2022. Mental health therapists and psychiatrists who wish to access the platform this year are being welcomed and onboarded in priority sequence.
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutic technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies worldwide. Learn more at mindcure.comand follow us on LinkedIn, Facebook, TwitterY Instagram.
On behalf of the Board of Directors
Kelsey RamsdenPresident and CEO
Phone: 1-888-593-8995
forward-looking information
Certain information presented in this press release may constitute “forward-looking information” within the meaning of applicable securities laws with respect to MINDCURE and its business. Forward-looking information can generally be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan” , “predict”, “project”, “subject to”, “will”, “would” and similar terms and phrases.
Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE’s management, including, but not limited to: the impact of the COVID-19 pandemic on the Canadian economy and MINDCURE’s business, and the extent and duration of said impact; any changes in laws or regulations that adversely affect MINDCURE’s business; the Company will develop its products as expected and that they will achieve the expected results; there will be demand for MINDCURE products in the future; no unforeseen expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates to provide mental health treatment solutions; that the strategic partnerships initiated by the Company will create the opportunities and expected results; that MINDCURE will promote wellness around the world; and that HIPAA compliance certification will have a positive impact on the commercial deployment of iSTRYM.
Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans regarding the future, and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently involves known and unknown risks and uncertainties about actual and future results and involves significant risks and uncertainties and should not be construed as a guarantee of future performance or results, as actual results may differ materially from those expressed or implicit in said information. prospective information. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in the forward-looking information presented, there may be other factors that cause actual results, performance or achievements to differ from those anticipated. , estimated or intended for. Accordingly, readers should not place undue reliance on any forward-looking statement, as no forward-looking information can be guaranteed.
Except as required by applicable securities laws, forward-looking statements speak only as of the date they are made and MINDCURE undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
The CSE has neither approved nor disapproved the content of this news release and the CSE accepts no responsibility for the adequacy or accuracy of this news release.
View original content to download media:https://www.prnewswire.com/news-releases/mindcure-hires-dr-clare-purvis-from-headspace-to-the-position-of-jefe-official-product-to-advance-mental-health- digital-therapeutic-platform-301474466.html
SOURCE Mind Cure Health Inc.
